VRTX vs CRSP
VRTX and CRSP side by side — valuation & fundamentals (public data).
Key statistics
| Metric | VRTXVERTEX PHARMACEUTICALS INC / MA | CRSPCRISPR THERAPEUTICS AG |
|---|---|---|
| Market cap | $122.73B | $4.59B |
| P/E (TTM) | 28.7 | — |
| P/B | 6.34 | — |
| P/S | 10.2x | 1308.7x |
| Revenue | $12.22B(TTM) | — |
| Revenue growth (YoY) | 8.9% | -90.6% |
| Net income | $4.34B(TTM) | — |
| Earnings growth (YoY) | 838.1% | -58.8% |
| EPS, diluted | $16.85(TTM) | — |
| EBIT margin | 34.8% | -18933.6% |
| ROE | 20.4% | -32.1% |
| ROIC | 25.4% | -33.6% |
| 1y total return | +3.2% | -19.3% |
Figures from SEC filings · for reference only · not investment advice
Growth of $10,000: VRTX vs CRSP
| Metric | VRTX | CRSP |
|---|---|---|
| End value | $59.1K | $33.8K |
| Total return | +490.6% | +238.1% |
| CAGR | +19.9% | +13.3% |
| Volatility | 32.7% | 64.2% |
| Sharpe | 0.60 | 0.45 |
| Sortino | 0.89 | 0.70 |
| Max drawdown | -41.6% | -85.1% |
Based on 2456 common trading days, 2016-10-19 → 2026-07-29 · risk-free 3.83% (current short-Treasury, held constant)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)